(NASDAQ: ARDX) Ardelyx's forecast annual revenue growth rate of 26.63% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.92%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.08%.
Ardelyx's revenue in 2026 is $398,234,000.On average, 13 Wall Street analysts forecast ARDX's revenue for 2026 to be $131,337,331,365, with the lowest ARDX revenue forecast at $114,176,056,132, and the highest ARDX revenue forecast at $143,551,649,728. On average, 11 Wall Street analysts forecast ARDX's revenue for 2027 to be $173,770,364,165, with the lowest ARDX revenue forecast at $144,287,861,875, and the highest ARDX revenue forecast at $195,169,111,295.
In 2028, ARDX is forecast to generate $191,517,207,475 in revenue, with the lowest revenue forecast at $132,117,278,888 and the highest revenue forecast at $259,982,507,420.